title: Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan.
abstract: OBJECTIVE
  Chemotherapy is an indispensable therapeutic approach for colorectal cancer both in the adjuvant and metastatic setting. Although chemotherapy-induced nausea and vomiting (CINV) is one of the most crucial adverse events, many aspects of CINV in patients with colorectal cancer remain unclear.
  
  
  METHODS
  This multicenter, prospective, observational study analyzed the data of 190 colorectal cancer patients scheduled for moderately emetogenic chemotherapy (MEC). The patients recorded the incidence of CINV and severity of nausea by visual analogue scales daily for 7 days after receiving chemotherapy.
  
  
  RESULTS
  All 190 patients received MEC and 99% of patients received antiemetic therapy in compliance with guidelines. Acute CINV was well controlled. 13 (6.8%) patients suffered from acute nausea and 4 (2.1%) experienced acute vomiting, whereas the prevalence of delayed CINV was relatively high. Delayed nausea occurred in 71 (37.4%) patients and delayed vomiting in 24 (12.6%). History of motion sickness was a significant independent risk factor for delayed nausea (Odd ratio 3.89, 95% confidence interval 1.49-10.19, p = 0.0056).
  
  
  CONCLUSIONS
  The compliance with CINV guidelines in colorectal cancer chemotherapy was quite high and led to good control of chemotherapy-induced vomiting in Japan. However, the incidence of delayed nausea remained high in patients receiving MEC.
authors.affiliation: a Department of Medical Oncology , Tonan Hospital , Sapporo , Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tsuji
authors.affiliation: b Department of Gastroenterological Surgery , Kumamoto University , Kumamoto , Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Baba
authors.affiliation: c Department of Clinical Oncology , Osaka City General Hospital , Osaka , Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Takeda
authors.affiliation: d Cancer Treatment Center , Kochi Medical School Hospital , Nankoku , Japan.
authors.forename: Michiya
authors.initials: M
authors.lastname: Kobayashi
authors.affiliation: e Department of Surgery and Science , Kyushu University , Fukuoka , Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Oki
authors.affiliation: f Cancer Chemotherapy Center , Osaka Medical College Hospital , Takatsuki , Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Gotoh
authors.affiliation: g Department of Surgical Oncology , Gifu University , Gifu , Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshida
authors.affiliation: h Department of Cancer Information Research , National Hospital Organization Kyushu Cancer Center , Fukuoka , Japan.
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Shimokawa
authors.affiliation: i Division of Gastrointestinal Surgery , Kobe University Hospital , Kobe , Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Kakeji
authors.affiliation: j Department of Internal Medicine, Division of Clinical Oncology and Hematology , The Jikei University School of Medicine , Tokyo , Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Aiba
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D016017:Odds Ratio; D015995:Prevalence; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D014839:Vomiting / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents
keywords: CINV; antiemetic agents; antiemetic guidelines; colorectal cancer; oxaliplatin based regimen